Peter Persich

Peter Persich is currently a CMC QA Manager at Bayer, where they lead authoring teams for NDAs, BLAs, and variations while managing the generation of Technical Registration Documents. Previously, Peter served as a Scientific Manager at Grünenthal Group, focusing on abuse deterrent formulations and CMC development related to the opioid crisis. Their career also includes roles at Janssen Pharmaceutical Companies, where they conducted drug stability testing and managed CMC projects, and as a post-doc in the Department of Analytical Development. Peter holds a PhD in Organic Chemistry from the Max Planck Society and a Diplom with distinction from Westfälische Wilhelms-Universität Münster.